Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD

Trial ID: NCT05412394

Interventional - Phase 4 - Recruiting

The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.

Conditions

• Duchenne Muscular Dystrophy

Interventions

• Prednisolone

Eligibility

Inclusion criteria

• Subjects ages 1 month through 30 months
• Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.

Exclusion criteria

• Prior treatment with Glucocorticosteroids

Sponsor

Anne M. Connolly, Children's Hospital Medical Center, Cincinnati, Muscular Dystrophy Association, University of Texas, Virginia Commonwealth University, Ann & Robert H Lurie Children's Hospital of Chicago

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows